Single User License
INR 133960
Site License
INR 267920
Corporate User License
INR 401880

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Nasopharyngeal Cancer-Pipeline Review, H2 2015

Nasopharyngeal Cancer-Pipeline Review, H2 2015


  • Products Id :- GMDHC6863IDB
  • |
  • Pages: 94
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Nasopharyngeal Cancer-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Nasopharyngeal Cancer-Pipeline Review, H2 2015', provides an overview of the Nasopharyngeal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Nasopharyngeal Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Nasopharyngeal Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Nasopharyngeal Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Nasopharyngeal Cancer-Overview 10

Pipeline Products for Nasopharyngeal Cancer-Comparative Analysis 11

Nasopharyngeal Cancer-Therapeutics under Development by Companies 12

Nasopharyngeal Cancer-Therapeutics under Investigation by Universities/Institutes 13

Nasopharyngeal Cancer-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Nasopharyngeal Cancer-Products under Development by Companies 17

Nasopharyngeal Cancer-Products under Investigation by Universities/Institutes 18

Nasopharyngeal Cancer-Companies Involved in Therapeutics Development 19

Ambrx, Inc. 19

AVEO Pharmaceuticals, Inc. 20

BioDiem Ltd 21

Celgene Corporation 22

Cyclacel Pharmaceuticals, Inc. 23

F. Hoffmann-La Roche Ltd. 24

GlaxoSmithKline Plc 25

Merck & Co., Inc. 26

Otsuka Holdings Co., Ltd. 27

Pharmacyclics, Inc. 28

Theravectys SA 29

Zhejiang BetaPharma Co., Ltd. 30

Nasopharyngeal Cancer-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Combination Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

abexinostat hydrochloride-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

azacitidine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Cell Therapy 2 for Oncology and Infectious Disease-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Cell Therapy for Metastatic Nasopharyngeal Carcinoma and Colorectal Cancer-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Cell Therapy for Nasopharingeal Carcinoma-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Cell Therapy to Target Latent Membrane Protein-2 for Oncology-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Cell Therapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Cell Therapy to Target LMP-1 and LMP-2 for Oncology-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

DC-120-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Dendritic Cells + Cytokine Induced Killer Cells-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

EBV-nRNA-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

ficlatuzumab-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Gene Therapy to Activate p53 for Oncology-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

GSK-2849330-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

icotinib hydrochloride-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

MK-2206-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

NEO-212-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

nimotuzumab-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

OPB-51602-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

RO-5203280-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

seliciclib-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecules for Nasopharyngeal and Colon Cancers-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Stem Cell Therapy for Oncology-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Vaccine for EBV Associated Cancer-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Vaccine to Target EBV for Nasopharyngeal Carcinoma-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Nasopharyngeal Cancer-Recent Pipeline Updates 80

Nasopharyngeal Cancer-Dormant Projects 87

Nasopharyngeal Cancer-Product Development Milestones 88

Featured News & Press Releases 88

Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 88

May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 89

Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 89

Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 90

Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 90

Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 91

Appendix 93

Methodology 93

Coverage 93

Secondary Research 93

Primary Research 93

Expert Panel Validation 93

Contact Us 93

Disclaimer 94

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, H2 2015 10

Number of Products under Development for Nasopharyngeal Cancer-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 13

Comparative Analysis by Late Stage Development, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Development, H2 2015 16

Products under Development by Companies, H2 2015 17

Products under Investigation by Universities/Institutes, H2 2015 18

Nasopharyngeal Cancer-Pipeline by Ambrx, Inc., H2 2015 19

Nasopharyngeal Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 20

Nasopharyngeal Cancer-Pipeline by BioDiem Ltd, H2 2015 21

Nasopharyngeal Cancer-Pipeline by Celgene Corporation, H2 2015 22

Nasopharyngeal Cancer-Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 23

Nasopharyngeal Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 24

Nasopharyngeal Cancer-Pipeline by GlaxoSmithKline Plc, H2 2015 25

Nasopharyngeal Cancer-Pipeline by Merck & Co., Inc., H2 2015 26

Nasopharyngeal Cancer-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 27

Nasopharyngeal Cancer-Pipeline by Pharmacyclics, Inc., H2 2015 28

Nasopharyngeal Cancer-Pipeline by Theravectys SA, H2 2015 29

Nasopharyngeal Cancer-Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015 30

Assessment by Monotherapy Products, H2 2015 31

Assessment by Combination Products, H2 2015 32

Number of Products by Stage and Target, H2 2015 34

Number of Products by Stage and Mechanism of Action, H2 2015 36

Number of Products by Stage and Route of Administration, H2 2015 38

Number of Products by Stage and Molecule Type, H2 2015 40

Nasopharyngeal Cancer Therapeutics-Recent Pipeline Updates, H2 2015 80

Nasopharyngeal Cancer-Dormant Projects, H2 2015 87

List of Figures

Number of Products under Development for Nasopharyngeal Cancer, H2 2015 10

Number of Products under Development for Nasopharyngeal Cancer-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 13

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Products, H2 2015 16

Assessment by Monotherapy Products, H2 2015 31

Number of Products by Top 10 Targets, H2 2015 33

Number of Products by Stage and Top 10 Targets, H2 2015 33

Number of Products by Top 10 Mechanism of Actions, H2 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 35

Number of Products by Top 10 Routes of Administration, H2 2015 37

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 37

Number of Products by Top 10 Molecule Types, H2 2015 39

Number of Products by Stage and Top 10 Molecule Types, H2 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ambrx, Inc.

AVEO Pharmaceuticals, Inc.

BioDiem Ltd

Celgene Corporation

Cyclacel Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Merck & Co., Inc.

Otsuka Holdings Co., Ltd.

Pharmacyclics, Inc.

Theravectys SA

Zhejiang BetaPharma Co., Ltd.

Nasopharyngeal Cancer Therapeutic Products under Development, Key Players in Nasopharyngeal Cancer Therapeutics, Nasopharyngeal Cancer Pipeline Overview, Nasopharyngeal Cancer Pipeline, Nasopharyngeal Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com